{"id":817363,"date":"2025-02-25T07:26:07","date_gmt":"2025-02-25T12:26:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/"},"modified":"2025-02-25T07:26:07","modified_gmt":"2025-02-25T12:26:07","slug":"oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/","title":{"rendered":"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <i>Conference call and webcast to take place on <span class=\"xn-chron\">Friday, March 7, 2025<\/span>, at <span class=\"xn-chron\">8:30 a.m. ET<\/span><\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span> and <span class=\"xn-location\">CALGARY, AB<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 25, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0 Oncolytics<span> Biotech<\/span><sup>\u00ae<\/sup><span>\u00a0Inc. (<\/span>NASDAQ<span>: <\/span>ONCY<span>) (<\/span>TSX<span>: <\/span>ONC<span>), a leading clinical-stage company specializing in <\/span>immunotherapy<span> for oncology, today announced that it will host a conference call and webcast on <span class=\"xn-chron\">Friday, March 7, 2025<\/span>, at <span class=\"xn-chron\">8:30 a.m. ET<\/span> to discuss a corporate update and financial results for the fourth quarter and full year 2024.<\/span><\/p>\n<div id=\"prni_dvprnejpgdbdfleft\" dir=\"ltr\" style=\"width: 100%;text-align: left\">\n        <img decoding=\"async\" id=\"prnejpgdbdfleft\" title=\" Oncolytics Biotech\u00ae Inc.Logo\" src=\"https:\/\/mma.prnewswire.com\/media\/2408622\/5171389\/Oncolytics_Biotech_Inc_Logo.jpg\" alt=\" Oncolytics Biotech\u00ae Inc.Logo\" align=\"middle\" \/>\n      <\/div>\n<p>\n        <b><br \/>\n          <u>Conference Call &amp; Webcast<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>Date:<\/b><br \/>\n        <span class=\"xn-chron\">Friday, March 7, 2025<\/span><br \/>\n        <br \/>\n        <b>Time:<\/b><br \/>\n        <span class=\"xn-chron\">8:30 a.m. ET<\/span><br \/>\n        <br \/>\n        <b>Dial In \u2013 North American Toll-Free:<\/b> (888) 510-2154<br \/><b>Dial In \u2013 International:<\/b> (437) 900-0527<br \/><b>RapidConnect:<\/b>\u00a0to join the conference call without operator assistance, please <a href=\"https:\/\/emportal.ink\/3EtvpHT\" target=\"_blank\" rel=\"nofollow\">click here<\/a><br \/><b>Conference ID <\/b>(if needed)<b>:<\/b> 48422 <br \/><b>Webcast:<\/b>\u00a0please <a href=\"https:\/\/app.webinar.net\/5XOnPEwAkBy\" target=\"_blank\" rel=\"nofollow\">click here<\/a><\/p>\n<p>A webcast of the call will also be available on the Investor Relations page of Oncolytics&#8217; website, available by clicking\u00a0<a href=\"https:\/\/oncolyticsbiotech.com\/investor-overview\/events\/\" target=\"_blank\" rel=\"nofollow\">here<\/a>, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (<span class=\"xn-location\">North America<\/span>) or (289) 819-1450 (International) and using replay code: 48422#.<\/p>\n<p>\n        <b>About Oncolytics Biotech Inc.<\/b>\n      <\/p>\n<p>Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype &#8212; turning &#8220;cold&#8221; tumors &#8220;hot&#8221; &#8212; through innate and adaptive immune responses to treat a variety of cancers.<\/p>\n<p>Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit:\u00a0<a href=\"http:\/\/www.oncolyticsbiotech.com\/\" target=\"_blank\" rel=\"nofollow\">www.oncolyticsbiotech.com<\/a>\u00a0or follow the company on social media on <a href=\"https:\/\/www.linkedin.com\/company\/oncolytics-biotech-inc.\/\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>\u00a0and on X @<a href=\"https:\/\/twitter.com\/oncolytics\" target=\"_blank\" rel=\"nofollow\">oncolytics<\/a>.<\/p>\n<p>\u00a0<\/p>\n<p>\n        <b>Company Contact<br \/><\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-person\">Jon Patton<\/span><br \/>\n          <br \/>\n        <\/span>Director of IR &amp; Communication <br \/><a href=\"mailto:jpatton@oncolytics.ca\" target=\"_blank\" rel=\"nofollow\">jpatton@oncolytics.ca<\/a>\u00a0<\/p>\n<p>\n        <b>Investor Relations for Oncolytics <br \/><\/b><br \/>\n        <span class=\"xn-person\">Timothy McCarthy<\/span><br \/>\n        <br \/>LifeSci Advisors <br \/>+1-917-679-9282 <br \/><a href=\"mailto:tim@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow\">tim@lifesciadvisors.com<\/a>\u00a0<\/p>\n<p>\n        <b>Media Contact for Oncolytics <br \/><\/b><br \/>\n        <span class=\"xn-person\">Michael Rubenstein<\/span><br \/>\n        <br \/>LifeSci Communications <br \/><a href=\"mailto:mrubenstein@lifescicomms.com\" target=\"_blank\" rel=\"nofollow\">mrubenstein@lifescicomms.com<\/a>\u00a0<\/p>\n<p>Logo: <a href=\"https:\/\/mma.prnewswire.com\/media\/2408622\/5171389\/Oncolytics_Biotech_Inc_Logo.jpg\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/2408622\/5171389\/Oncolytics_Biotech_Inc_Logo.jpg<\/a><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN26466&amp;sd=2025-02-25\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-302384064.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-302384064.html<\/a><\/p>\n<p>SOURCE  Oncolytics Biotech\u00ae Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN26466&amp;Transmission_Id=202502250700PR_NEWS_USPR_____LN26466&amp;DateId=20250225\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 \/PRNewswire\/ &#8212;\u00a0 Oncolytics Biotech\u00ae\u00a0Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call &amp; Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ET Dial In \u2013 North American Toll-Free: (888) 510-2154Dial In \u2013 International: (437) 900-0527RapidConnect:\u00a0to join the conference call without operator assistance, please click hereConference ID (if needed): 48422 Webcast:\u00a0please &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-817363","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 \/PRNewswire\/ &#8212;\u00a0 Oncolytics Biotech\u00ae\u00a0Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call &amp; Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ET Dial In \u2013 North American Toll-Free: (888) 510-2154Dial In \u2013 International: (437) 900-0527RapidConnect:\u00a0to join the conference call without operator assistance, please click hereConference ID (if needed): 48422 Webcast:\u00a0please &hellip; Continue reading &quot;Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-25T12:26:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2408622\/5171389\/Oncolytics_Biotech_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights\",\"datePublished\":\"2025-02-25T12:26:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/\"},\"wordCount\":387,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2408622\\\/5171389\\\/Oncolytics_Biotech_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/\",\"name\":\"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2408622\\\/5171389\\\/Oncolytics_Biotech_Inc_Logo.jpg\",\"datePublished\":\"2025-02-25T12:26:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2408622\\\/5171389\\\/Oncolytics_Biotech_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2408622\\\/5171389\\\/Oncolytics_Biotech_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/","og_locale":"en_US","og_type":"article","og_title":"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights - Market Newsdesk","og_description":"PR Newswire Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 \/PRNewswire\/ &#8212;\u00a0 Oncolytics Biotech\u00ae\u00a0Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call &amp; Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ET Dial In \u2013 North American Toll-Free: (888) 510-2154Dial In \u2013 International: (437) 900-0527RapidConnect:\u00a0to join the conference call without operator assistance, please click hereConference ID (if needed): 48422 Webcast:\u00a0please &hellip; Continue reading \"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-25T12:26:07+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2408622\/5171389\/Oncolytics_Biotech_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights","datePublished":"2025-02-25T12:26:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/"},"wordCount":387,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2408622\/5171389\/Oncolytics_Biotech_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/","name":"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2408622\/5171389\/Oncolytics_Biotech_Inc_Logo.jpg","datePublished":"2025-02-25T12:26:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2408622\/5171389\/Oncolytics_Biotech_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2408622\/5171389\/Oncolytics_Biotech_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncolytics Biotech\u00ae to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=817363"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817363\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=817363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=817363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=817363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}